Parameter | Overall | AKI Stage | p value* | |||
---|---|---|---|---|---|---|
n = 295 | 0 (n = 55) | 1 (n = 23) | 2 (n = 56) | 3 (n = 161) | ||
Baseline characteristics | ||||||
 Age, years (IQR) | 63 (51–72) | 60 (45–71) | 62 (50–77) | 65 (54–71) | 63 (52–71) | 0.325 |
 Sex (male), n (%) | 201 (68 %) | 31 (56 %) | 19 (83 %) | 35 (63 %) | 116 (72 %) | 0.086 |
 SAPS II (IQR) | 62 (45–79) | 50 (33–68) | 52 (37–73) | 59 (38–75) | 70 (52–86) | <0.001 |
 SOFA (IQR) | 11 (8–15) | 10 (7–12) | 9 (7–12) | 10(6–13) | 12 (8–16) | <0.001 |
 Respiratory rate, bpm (IQR) | 20 (16–25) | 18 (15–22) | 18 (15–27) | 20 (16–25) | 21 (17–27) | 0.080 |
 Body temperature, C° (IQR) | 36.0 (34.8–36.8) | 35.5 (33.6–36.5) | 35.6 (33.5–36.5) | 36.4 (35.2–36.9) | 36.1 (35.0–36.8) | 0.893 |
 Heart rate, bpm (IQR) | 81 (65–104) | 79 (61–95) | 83 (60–107) | 79 (60–98) | 83 (66–108) | 0.119 |
 Mean arterial pressure, mmHg (IQR) | 68 (57–79) | 73 (63–83) | 72 (58–80) | 70 (61–83) | 65 (54–76) | <0.01 |
 Preexisting liver cirrhosis, n (%) | 22 (7 %) | 1 (2 %) | 0 | 5 (9 %) | 16 (10 %) | <0.05 |
Cause of HH | ||||||
 Cardiogenic shock, n (%)a | 133 (45 %) | 27 (49 %) | 15 (65 %) | 28 (50 %) | 63 (39 %) | <0.05 |
 Septic shock, n (%)a | 109 (37 %) | 12 (22 %) | 5 (22 %) | 14 (25 %) | 78 (48 %) | <0.001 |
 Hemorrhagic shock, n (%) | 8 (3 %) | 0 | 0 | 1 (2 %) | 7 (4 %) | 0.081 |
Therapy | ||||||
 Mechanical ventilation, n (%) | 225 (76 %) | 36 (66 %) | 19 (83 %) | 35 (63 %) | 135 (84 %) | <0.01 |
 Vasopressor use, n (%) | 247 (84 %) | 38 (69 %) | 18 (78 %) | 35 (80 %) | 146 (91 %) | <0.001 |
RRT, n (%) | 122 (41 %) | 0 | 0 | 0 | 122 (76 %) | <0.001 |
Laboratory parameters on admission | ||||||
 Arterial lactate, mmol/l (IQR) | 3.5 (1.7–8.2) | 2.0 (1.2–4.4) | 2.7 (1.6–5.7) | 3.5 (2.1–6.9) | 4.3 (2.1–10.6) | <0.001 |
 Arterial pH (IQR) | 7.30 (7.20–7.40) | 7.39 (7.30–7.47) | 7.32 (7.28–7.39) | 7.32 (7.24–7.41) | 7.27 (7.15–7.36) | <0.001 |
 Sodium, mmol/l (IQR) | 138 (133–142) | 138 (133–140) | 140 (136–143) | 138 (133–141) | 138 (133–142) | 0.387 |
 Potassium, mmol/l (IQR) | 4.5 (3.9–5.2) | 4.1 (3.6–4.7) | 4.0 (3.7–4.4) | 4.5 (4.1–5.1) | 4.7 (4.1–5.5) | 0.906 |
 Albumin, g/l (IQR) | 29.3 (24.1–34.0) | 29 (24–32) | 30 (26–36) | 30 (24–35) | 29 (24–34) | 0.405 |
 AST, U/l (IQR) | 366 (73–1265) | 345 (77–781) | 474 (85–1341) | 699 (108–1599) | 248 (57–1475) | 0.142 |
 ALT, U/l (IQR) | 139 (39–706) | 129 (55–639) | 219 (54–631) | 217 (44–1470) | 124 (34–682) | 0.731 |
 INR (IQR) | 1.4 (1.2–1.9) | 1.3 (1.1–1.6) | 1.3 (1.1–1.4) | 1.4 (1.2–1.9) | 1.5 (1.2–2.1) | 0.142 |
 Bilirubin, mg/dl (IQR) | 1.3 (0.7–2.7) | 1.0 (0.6–2.1) | 0.9 (0.7–1.6) | 1.3 (0.8–3.1) | 1.4 (0.7–3.2) | <0.05 |
Outcome | ||||||
 28-day mortality, n (%) | 170 (58 %) | 17 (31 %) | 6 (26 %) | 25 (45 %) | 122 (76 %) | <0.001 |